Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2415-2423

  Grim, Jon ^b   D'Amico, Anna ^b,c   Frizelle, Sandra ^a   Zhou, Joan ^a   Kratzke, Robert A ^a   Curiel, David T ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Alabama   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TARGET CELL DESTRUCTION; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL SURVIVAL; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DRUG RESISTANCE, NEOPLASM; G1 PHASE; GENE THERAPY; GENES, P16; GENES, RETINOBLASTOMA; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PACLITAXEL; RECOMBINANT PROTEINS; RETINOBLASTOMA PROTEIN; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0031418312     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Sherr, C. J. Cancer cell cycles. Science (Washington DC)., 274: 1672-1677, 1996.
2. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
3. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
4. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
5. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
6. Cairns, P., Tokino, K., Eby, Y., and Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res., 54: 1422-1424, 1994.
7. Stadler, W. M., Sherman, J., Bohlander, S. K., Roulston, D., Dreyling, M., Rukstalis, D., and Olopade, O. I. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res., 54: 2060-2063, 1994.
8. Miyao, N., Tsai, Y. C., Lerner, S. P., Olumi, A. F., Spruck, C. H., III, Gonzalez-Zulueta, M., Nichols, P. W., Skinner, D. G., and Jones, P. A. Role of chromosome 9 in human bladder cancer. Cancer Res., 53: 4066-4070, 1993.
9. Orlow, I., Lacombe, L., Hannon, G. J., Serrano, M., Pellicer, I., Dalbagni, G., Reuter, V. E., Zhang, Z. F., Beach, D., and Cordon-Cardo, C. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl. Cancer Inst., 87: 1524-1529, 1995.
10. Geradts, J., Kratzke, R. A., Niehans, G. A., and Lincoln, C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
11. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
12. Roth, J. A. Gene replacement strategies for cancer. Isr. J. Med. Sci., 32: 89-94, 1996.
13. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
14. Fujiwara, T., Cai, D. W., Georges, R. N., Mukhopadhyay, T., Grimm, E. A., and Roth, J. A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst., 86: 1458-1462, 1994.
15. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
16. Kohn, K. W. Regulatory genes and drug sensitivity. J. Natl. Cancer Inst., 88: 1255-1256, 1996.
17. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
18. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
19. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
20. Frisch, S. M., and Dolter, K. E. Adenovirus Ela-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer Res., 55: 5551-5555, 1995.
21. Barnes, M. N., Deshane, J. S., Siegal, G. P., Alvarez, R. D., and Curiel, D. T. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell sensitivity. Clin. Cancer Res., 2: 1089-1095, 1996.
22. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
23. Jin, X., Nguyen, D., Zhang, W. W., Kyritsis, A. P., and Roth, J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res., 55: 3250-3253, 1995.
24. Wu, Q., Possati, L., Montesi, M., Gualandi, F., Rimessi, P., Morelli, C., Trabanelli, C., and Barbanti-Brodano, G. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9. Int. J. Cancer, 65: 840-846, 1996.
25. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
26. Kratzke, R. A., Shimizu, E., Geradts, J., Gerster, J. L., Segal, S., Otterson, G. A., and Kaye, F. J. RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Growth Differ., 4: 629-635, 1993.
27. Kratzke, R. A., Otterson, G. A., Lincoln, C. E., Ewing, S., Oie, H., Geradts, J., and Kaye, F. J. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J. Natl. Cancer Inst., 87: 11870-11875, 1995.
28. Becker, T. C., Noel, R. J., Coats, W. S., Gomez-Foix, A. M., Alam, T., Gerard, R. D., and Newgard, C. B. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol., 43: 161-189, 1994.
29. Tang, D. C., Johnston, S. A., and Carbone, D. P. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther., 1: 15-20, 1994.
30. Kaye, F. J., Kratzke, R. A., Gerster, J. L., and Horowitz, J. M. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA, 87: 6922-6926, 1990.
31. Stone, S., Dayananth, P., and Kamb, A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res., 56: 3199-3202, 1996.
32. Horowitz, J. M., Yandell, D. W., Park, S. H., Canning, S., Whyte, P., Buchkovich, K., Harlow, E., Weinberg, R. A., and Dryja, T. P. Point mutational inactivation of the retinoblastoma antioncogene. Science (Washington DC), 243: 937-940, 1989.
33. Goodrich, D. W., Chen, Y., Scully, P., and Lee, W. H. Expression of the retinoblastoma gene product in bladder carcinoma cells associates with a low frequency of tumor formation. Cancer Res., 52: 1968-1973, 1992.
34. Fueyo, J., Gomez-Manzano, C., Yung, W. K., Clayman, G. L., Liu, T. J., Bruner, J., Levin, V. A., and Kyritsis, A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene, 12: 103-110, 1996.
35. Feng, M., Cabrera, G., Deshane, J., Scanlon, K. J., and Curiel, D. T. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res., 55: 2024-2028, 1995.
36. Bass, C., Cabrera, G., Elgavish, A., Robert, B., Siegal, G. P., Anderson, S. C., Maneval, D. C., and Curiel, D. T. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther., 2: 97-104, 1995.
37. Schrump, D. S., Chen, G. A., Consuli, U., Jin, X., and Roth, J. A. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16-INK4. Cancer Gene Ther., 3: 357-364, 1996.
38. Zhou, X., Suzuki, H., Lei, J., Cole, K., Yin, J., Suzuki, Y., Abraham, J. M., Shimada, Y., Imamura, M., Chan, T., and Hannon, G. J. Growth suppression of esophageal cancer cells by p16-INK4 and p15-INK4B in vitro. Cancer J. Sci. Am., 2: 221-224, 1996.
39. Scambia, G., Benedetti-Panici, P., Ferrandina, G., Distefano, M., Salerno, G., Romanini, M. E., Fagotti, A., and Mancuso, S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer, 72: 361-366, 1995.
40. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
41. Tsai, C. M., Yu, D., Chang, K. T., Wu, L. H., Perng, R. P., Ibrahim, N. K., and Hung, M. C. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J. Natl. Cancer Inst., 87: 682-684, 1995.
42. Medema, R. H., Herrera, R. E., Lam, F., and Weinberg, R. A. Growth suppression by p16ink4 requires functional retinoblastoma protein. Proc. Natl. Acad. Sci. USA, 92: 6289-6293, 1995.
43. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr., 15: 55-61, 1993.
44. Rowinsky, E. K., Onetto, N., Canetta, R. M., and Arbuck, S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol., 19: 646-662, 1992.